Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Klocker

Showing results (101-110 of 142) with videos related to

Pageof 15
Sort By:
Genomics|April 11, 2000
Peptide YY-2 (PYY2) and pancreatic polypeptide-2 (PPY2): species-specific evolution of novel members of the neuropeptide Y gene familyM Couzens, M Liu, C Tüchler, et al.
Cancer Research|January 19, 1999
Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell linesT Putz, Z Culig, I E Eder, et al.
European Urology|January 1, 1995
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factorZ Culig, A Hobisch, M V Cronauer, et al.
The Prostate|July 1, 1997
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cellsZ Culig, A Hobisch, A Hittmair, et al.
Cancer Research|October 15, 1994
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factorZ Culig, A Hobisch, M V Cronauer, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 1, 1993
Characterization of two point mutations in the androgen receptor gene of patients with perineoscrotal hypospadiaF Kaspar, A C Cato, A Denninger, et al.
Urology|September 11, 2001
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaG Bartsch, W Horninger, H Klocker, et al.
Prostate Cancer and Prostatic Diseases|October 30, 2013
[-2]proPSA is an early marker for prostate cancer aggressivenessI Heidegger, H Klocker, E Steiner, et al.
British Journal of Cancer|July 4, 2014
EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205P Massoner, T Thomm, B Mack, et al.
The Prostate|June 1, 1996
Regulation of prostatic growth and function by peptide growth factorsZ Culig, A Hobisch, M V Cronauer, et al.
Pageof 15

Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Genomics|April 11, 2000
Peptide YY-2 (PYY2) and pancreatic polypeptide-2 (PPY2): species-specific evolution of novel members of the neuropeptide Y gene familyM Couzens, M Liu, C Tüchler, et al.
Cancer Research|January 19, 1999
Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell linesT Putz, Z Culig, I E Eder, et al.
European Urology|January 1, 1995
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factorZ Culig, A Hobisch, M V Cronauer, et al.
The Prostate|July 1, 1997
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cellsZ Culig, A Hobisch, A Hittmair, et al.
Cancer Research|October 15, 1994
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factorZ Culig, A Hobisch, M V Cronauer, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 1, 1993
Characterization of two point mutations in the androgen receptor gene of patients with perineoscrotal hypospadiaF Kaspar, A C Cato, A Denninger, et al.
Urology|September 11, 2001
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaG Bartsch, W Horninger, H Klocker, et al.
Prostate Cancer and Prostatic Diseases|October 30, 2013
[-2]proPSA is an early marker for prostate cancer aggressivenessI Heidegger, H Klocker, E Steiner, et al.
British Journal of Cancer|July 4, 2014
EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205P Massoner, T Thomm, B Mack, et al.
The Prostate|June 1, 1996
Regulation of prostatic growth and function by peptide growth factorsZ Culig, A Hobisch, M V Cronauer, et al.
Pageof 15